A number of studies have shown that coronary artery disease severity is associated with the e2/e3/e4 polymorphism in the coding region of the apolipoprotein E gene. In this study, we investigated whether the severity of the disease was also influenced by a functional polymorphism (À219 G4T) in the promoter of the gene, and if so, whether the effects of the two polymorphisms were independent. A cohort of 1170 patients with angiographically documented coronary artery disease were genotyped for the two polymorphisms. The frequency of the e4 allele of the e2/e3/e4 polymorphism increased linearly with increasing number of diseased vessels, so did the À219T allele of the À219 G4T polymorphism. In the sample as a whole, logistic regression analyses indicated that compared with the G/G genotype, the T/T genotype conferred an odds ratio of 1.598 (95% CI ¼ 1.161 -2.201, P ¼ 0.004) in favor of increased disease severity, and the relationship remained significant after adjustment for e2/e3/e4 polymorphism genotypes, plasma cholesterol and triglyceride levels, and other risk factors. The effect of the T/T genotype on disease severity was more significant in patients who did not carry the e4 allele (OR ¼ 1.510, 95% CI ¼ 1.028 -2.221) than in e4 allele carriers (OR ¼ 1.303, 95% CI ¼ 0.619-2.742). There was considerable linkage disequilibrium between the two polymorphisms (q ¼ 0.9, Po0.001). Logistic regression analysis showed that the À219T-e4 haplotype conferred an odds ratio of 1.488 (95% CI ¼ 1.133 -1.954). These findings suggest that the À219 G4T and e2/e3/e4 polymorphisms, which may affect respectively the quantity and quality of apoE, have independent and possibly additive effects on coronary artery disease severity.
Introduction
Apolipoprotein E (ApoE) serves as a ligand mediating the binding of chylomicron remnants and very-low-density lipoprotein remnants to lipoprotein receptors on liver cells, thus facilitating the clearance of these atherogenic lipoproteins from the plasma. 1 In addition to this important role, apoE has other antiatherogenic properties. 2 Particularly noteworthy is that apoE is expressed in macrophagederived lipid-laden foam cells in atherosclerotic lesions and facilitates cholesterol efflux from such cells. 2 -5 ApoEdeficient mice develop severe hypercholesterolemia and diffuse atherosclerotic lesions. 6 Expressing apoE in macrophages in such apoE-null mice can markedly attenuate the development of atherosclerosis, even in the presence of high levels of circulating atherogenic lipoproteins. 7 There is compelling evidence of an association between variation in the apoE gene and risk and severity of coronary artery disease (CAD) and Alzheimer's disease. The e2/e3/e4 polymorphism in the coding region of the gene has been studied extensively, with the e4 allele consistently found to be associated with increased risk of these diseases. 8, 9 The e2, e3 and e4 alleles, respectively, encode the apoE2, apoE3 and apoE4 isoforms that differ in amino-acid sequence at residues 112 and 158, with the E2 isoform having a cysteine at both sites, the E3 isoform having a cysteine and an arginine, respectively, and the E4 isoform possessing an arginine at both residues. Several polymorphisms in the promoter of the gene have also been identified, and it has been shown that the À219 G4T polymorphism exerts an allele-specific effect on apoE expression such that the T allelic promoter has a lower transcriptional activity than the G allelic promoter. 10 -13 Recently, it has been reported that individuals carrying the T allele have lower apoE concentrations in the plasma and are at increased risk of myocardial infarction. 14 Genetic factors for multifactorial disorders such as CAD may be classified into disease susceptibility genes and disease-modifying genes. The former may contribute to the initiation of the disease process, whereas the latter may influence the progression and outcome of the disease after it has been initiated. Previous studies have indicated that the e2/e3/e4 polymorphism is associated with the severity of CAD. 15 -17 In this study, we investigated whether the À219 G4T polymorphism also had an impact on disease severity and if so, whether the effect of this promoter polymorphism was independent of the e2/e3/e4 polymorphism and plasma cholesterol levels. This might provide a better estimate of the contribution of the apoE gene to CAD and insights into the underlying mechanisms. It is plausible that the genetic basis of CAD is related not only to the qualitative change in the apoE protein resulting from the e2/e3/e4 polymorphism but also to quantitative differences in the apoE expression resulting from variation in the apoE gene promoter. Table 1 . In all, 54% of the patients had a previous history of myocardial infarction or unstable angina. Total cholesterol and triglyceride levels were measured by the clinical chemistry department of the Southampton General Hospital using standard quality controlled enzymatic methods. All coronary angiograms were assessed by one consultant cardiologist. A 10 ml blood sample was taken from each subject and DNA was extracted using a salt precipitation method as previously described.
Subjects and methods

Subjects
18
Genotyping Genotypes for the e2/e3/e4 and À219 C4T polymorphisms were determined using previously described methods. 11, 19 In brief, a sequence containing the e2/e3/e4 polymorphic site was amplified by PCR using primers 5 0 -AGAATTC GCCCCGGCCTGGTACAC-3 0 and 5 0 -TAAGCTTGGCACGG CTGTCCAAGGA-3 0 , and the amplicon was subjected to digestion with restriction endonuclease Hha I and gel electrophoresis. Similarly, a sequence containing the À219 G4T polymorphic site was amplified using PCR primers 5 0 -AGAATGGAGGAGGGTGCCTG-3 0 and 5 0 -ACT CAAGGATCCCAGACTTG-3 0 , followed by digestion with restriction enzyme BstN I and gel electrophoresis.
Statistical analysis
One-way ANOVA and w 2 tests were carried out to examine differences in quantitative and categorical variables between patient groups who had one, two or three coronary arteries with 450% stenosis, and between apoE genotypes. In these analyses, triglyceride values were log transformed to normalize the distribution. Logistic regression analysis was used to evaluate the effects (expressed as odds ratios) of genotypes on severity of CAD. In these analyses, the number of diseased vessels was entered as ordinal variable and the genotypes as independent variable. These were first carried out separately for the À219 G4T and e2/e3/e4 polymorphisms, and analyses were performed firstly without and then with adjustment for covariates including age, gender, body mass index, smoking habit, diabetes, hypertension and cholesterol and triglyceride levels. A subsequent logistic regression analysis was performed with À219 G4T genotypes and e2/e3/e4 genotypes both entered in the equation, to evaluate independent contributions of these polymorphisms to severity of CAD. Linkage disequilibrium between the À219 G4T and e2/ e3/e4 polymorphisms was examined by w 2 analysis. The association metric r between the two polymorphisms was obtained using the ALLASS program (http://cedar.genetics. soton.ac.uk/public_html/). Haplotype frequencies were estimated using the SNPHAP program (Clayton V0.2 2002, http://www-gene.cimr.ac.uk/clayton/software) that employs an EM algorithm. The relationship between alleles and disease was assessed by logistic regression analyses in which the independent variables were scores (as 1 or 0) for the presence/absence of an allele in an individual. The relation between haplotypes and disease was examined by scoring the two haplotypes in an individual in probability using the haplotype frequency estimates from the SNPHAP program. Haplotypes could be scored without error except where an individual was heterozygous at more than one locus. In these cases, the score was allocated as a probability at each of the possible haplotypes. The table of scores for each individual at each of the six possible haplotypes was used in stepwise logistic regression in which we, firstly, included and, secondly, corrected for covariates (age, gender, BMI and genotypes). This allowed the testing of a haplotype effect over and above an allelespecific effect on the trait.
Results
Demographic and clinical characteristics of the subjects We studied a cohort of 1170 patients with CAD documented angiographically as having 450% diameter stenosis in at least one major coronary artery. The characteristics of the subjects are summarized in Table 1 . There was a positive correlation between age and the number of coronary arteries with 450% stenosis. The severity of CAD was also associated with the male gender and types I and II diabetes. There was no statistically significant difference between patient groups in lipid levels, body mass index, smoking habit, and the rates of hypertension and family history of CAD.
The e2/e3/e4 polymorphism and CAD severity Allele frequencies in the SAS sample were fully consistent with previous studies in other Caucasian samples, including unselected population studies. In the SAS sample as a whole, the frequencies of the e2/e2, e2/e3, e3/e3, e3/e4, e4/e4 and e2/ e4 genotypes were 0.005 (n ¼ 6), 0. Since the e2/e2, e4/e4 and e2/e4 genotypes are rare, to facilitate valid statistical analyses, we adopted a strategy used in many previous studies 16, 20 such that the subjects were grouped into those carrying the e2 allele (ie e2/e2+e2/e3), those with the e3/e3 genotype, and those carrying the e4 allele (e3/e4+e4/e4), and the patients with the e2/e4 genotype were excluded as it would be difficult to assign them to any of the above groups. The frequency of e4 allele carriers increased linearly with increasing number of diseased vessels (P ¼ 0.045 by w 2 analysis, Table 2 ). Logistic regression analysis indicated that compared with the e3/e3 genotype, the genotypes with the e4 allele were associated with an odds ratio of 1.347 (95% CI ¼ 1.047-1.735, P ¼ 0.021) in favor of a more severe CAD, and this relationship remained significant after adjusting for covariates including cholesterol and triglyceride levels ( Table 2) . The À219 G4T polymorphism and CAD severity There was also a significant difference in the distribution of genotypes for the À219 G4T polymorphism between patients with either one, two or three diseased vessels, that is the frequency of the T/T genotype increased with increasing number of diseased vessels (P ¼ 0.017 by w 2 analysis, Table 2 ). Logistic regression analysis indicated that compared with the G/G genotype, the T/T genotype was associated with an odds ratio of 1.598 (95% CI ¼ 1.161 -2.201, P ¼ 0.004) and the T/G genotype associated with an odds ratio of 1.230 (95% CI ¼ 0.952 -1.589, P ¼ 0.114). This relationship remained after adjustment for plasma cholesterol and triglyceride levels and other risk factors (Table 2) .
Independent effects of the À219 G4T polymorphism and the e2/e3/e4 polymorphism on severity of CAD To test whether the effect of the À219 G4T polymorphism on CAD severity was independent of the e2/e3/e4 polymorphism, a logistic regression analysis was carried out with the genotypes for the À219 G4T and the genotypes for the e2/e3/e4 polymorphism all entered in the equation.
There was a significant interaction between the two polymorphisms ( Table 3) . The association between the T/T genotype of the À219 G4T polymorphism and increased CAD severity remained significant (odds ratio ¼ 1.459, 95% CI ¼ 1.040 -2.048, P ¼ 0.028, Table 3 ) after adjusting for the e2/e3/e4 polymorphism, indicating that the effect of the À219 G4T polymorphism was independent of the e2/e3/e4 polymorphism. To further assess the independence of the À219 G4T polymorphism, we stratified the sample into two groups according to the presence/absence of the e4 allele, and performed logistic regression analyses to test the effect of the À219 G4T polymorphism on CAD severity. The analyses indicated that the T/T genotype was significantly associated with greater CAD severity (odds ratio ¼ 1.510, 95% CI ¼ 1.028 -2.221, P ¼ 0.036) in patients who did not carry the e4 allele, and had a similar but smaller effect in e4 allele carriers, again suggesting that the effect of the À219 G4T polymorphism was independent of the e2/e3/e4 polymorphism. Similarly, effects of the e4 allele on CAD severity were consistent in the three À219 G4T genotype groups (Table 3) .
Linkage disequilibrium and haplotypic effects on CAD There was considerable linkage disequilibrium between the À219 G4T and e2/e3/e4 polymorphisms, with the À219T allele being associated with the e4 allele (r ¼ 0.9, Po0.001).
Since there could be additive effects from the two polymorphisms, we examined whether haplotypes harboring the deleterious alleles at both polymorphic sites had a greater effect on CAD than those carrying the deleterious allele at only one site. To address this question, the effects of all genotypes and haplotypes were assessed in a stepwise logistic regression analysis that allowed the testing of a haplotype effect over and above an allele-specific effect on the trait. In this analysis, only the À219T-e4 and À219T-e3 haplotypes remained significant, indicating that these haplotypes had greater effects than any single polymorphism alone. The À219T-e4 haplotype gave an odds ratio of 1.488 (95% CI ¼ 1.133 -1.954) in this analysis, compared with an odds ratio of 1.328 for the e4 allele and an odds ratio of 1.230 for the À219T allele when the two polymorphisms were examined individually (Table 4) .
ApoE genotypes and lipid levels
There was an association between the e2/e3/e4 polymorphism and plasma levels of cholesterol, with the mean cholesterol level being 3.5% higher in patients carrying the e4 allele and 1% lower in patients carrying the e2 allele, compared with those with the e3/e3 genotype (P ¼ 0.033, Table 5 ). Plasma levels of triglyceride were also different in these three genotype groups such that the mean triglyceride level was 17% higher in patients with e2 allele and 6% higher in patients with the e4 allele, than in the e3/e3 homozygotes (P ¼ 0.033, Table 5 ). These associations remained significant after adjustment for age, gender and lipid-lowering medication. In contrast, there was no significant difference in plasma levels of cholesterol and triglyceride between patients with different genotypes for the À219 G4T polymorphism. 
Discussion
In a large cohort of patients with angiographically documented CAD, we examined the relationship between severity of the disease and the À219 G4T and e2/e3/e4 polymorphisms in the apoE gene. The key findings of the study are that the two polymorphisms have independent effects on CAD severity and that haplotypes harboring the deleterious alleles in both polymorphic sites are associated with a further increase in CAD severity. This suggests that the progression of the disease may be influenced by both the qualitative change in the apoE protein arising from the e2/e3/e4 polymorphism and quantitative differences in the levels of apoE expression because of variation in the promoter of the gene. The results also indicate that the effect of these polymorphisms on CAD is not entirely accounted for by differences in plasma levels of cholesterol and triglyceride, but is likely also attributable to other possible mechanisms. For example, it is plausible that the efficiency of cholesterol efflux from macrophages is reduced in individuals carrying the deleterious alleles of the apoE gene, resulting in a more abundant accumulation of lipid-laden foam cells and more extensive atherosclerotic lesions.
The results of this angiography-based study are consistent with the findings of two previous studies of the e2/e3/ e4 polymorphism based on pathological examinations. In the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) cohort consisting of 720 Caucasian and African-American males who died of external causes at the age of 15 -34 years and subjected to autopsy, it was found that those carrying the e4 allele had significantly higher mean percent surface area involvement with atherosclerotic lesions in the aorta, compared with those with the e3/e3 genotype. 15 Similarly, in an autopsy study (Helsinki Sudden Death Study) of 700 men from Finland, the e4 allele was associated with a larger atherosclerotic lesion area in the right and left anterior descending coronary arteries in those o53 years old. 17 Three polymorphisms (À219 G4T, À427 C4T and À491 A4T) in the promoter of the apoE gene have been reported. 10 -13 A systematic scanning for variation in a 5.5 kb sequence spanning the entire ApoE genomic region did not detect any other common polymorphism in the promoter region of this gene in two Caucasian samples respectively consisting of 884 European-Americans and 452 Europeans. 21 Of the three promoter polymorphisms, the À219 G4T has the strongest effect on apoE gene expression as demonstrated by in vitro reporter assays and measurements of apoE mRNA levels in ex vivo brain tissues from patients with Alzheimer's disease. 12, 13 It has been
shown that plasma apoE concentration is lowest in individuals who are homozygous for the T allele and highest in homozygotes for the G allele. 14 It has also been reported that the À219 G4T polymorphism, but not the À427 C4T or À491 A4T variants, is associated with risk of myocardial infarction in a study of 567 myocardial infarction patients and 678 healthy control subjects. 14 The present study suggests that this functional promoter polymorphism can also affect CAD severity. Neither the study by Lambert et al 14 nor the present study detects a significant association between the À219 G4T polymorphism and plasma cholesterol and triglyceride levels, although the polymorphism has been shown to influence plasma apoE concentration. In contrast, the e2/e3/e4 polymorphism is thought to be one of the most important genetic factors on the regulation of cholesterol metabolism at the population level, with the e4 allele being associated with elevation and the e2 allele with a reduction of cholesterol levels. In this study, the e2/e3/e4 polymorphism was found to account for about 0.6% of the variance of total cholesterol levels in plasma, which is consistent with the findings from other studies. 22 Although the precise mechanism underlying the effect of the e2/e3/e4 polymorphism on lipid levels has not been defined, several hypothesis has been proposed. It has been demonstrated that compared with the E3 isoform, the E4 isoform has increased affinity and the E2 isoform has reduced affinity to lipoprotein receptors on liver cells. 23 Thus, it has been suggested that compared with E2 and E3, apoE4 competes more effectively with LDL for binding to receptors on liver cells for clearance, leading to increased LDL cholesterol levels. 23 Many studies have shown an association between the e4 allele and CAD susceptibility and severity. In contrast, the relationship of the e2 allele with CAD remains controversial. Although some studies have suggested that the e2 allele is associated with a reduced risk of CAD, other studies have not found such a protective effect. 8, 20, 24 The present study and many others have found that individuals carrying the e2 allele have lower cholesterol but increased triglyceride levels. 25 -27 This disparate effect of the e2 allele on the two lipids might explain why it may have a protective or unfavorable effect on CAD development.
The effects of apoE genotype on CAD may be modulated by other factors, for example, the strength of association between the apoE e2/e3/e4 polymorphism and CAD severity is reduced after taking other risk factors into account, including high-density lipoprotein and apolipoprotein B. 16 However, the apoE genotypic effects on CAD remain significant after adjustment for such covariates, 14, 16, 20 suggesting that apoE genotype is an independent risk factor for CAD. Although the relationship between the apoE gene and CAD is well established, most studies to date have been focused on the e2/e3/e4 polymorphism. The present study indicates that the À219 G4T polymorphism influences CAD severity, which is independent of and possibly additive to the effect of the e2/e3/e4 polymorphism. This allelic heterogeneity of the apoE gene in CAD may represent a paradigm for other disease genes for this and other common disorders.
